States Expand Oversight of Healthcare Transactions

Not long ago, a healthcare deal could feel like a private dinner party: a handful of executives, a stack of binders,
and one very stressed-out spreadsheet that someone swears is “the final version.” Now, more states are turning that
dinner party into a potluck with a sign-in table, a comment card box, and a chaperone who asks, politely but firmly,
“So… who exactly will be in charge of clinical decisions after closing?”

Across the United States, states are expanding oversight of healthcare transactionsespecially mergers, acquisitions,
affiliations, management agreements, and other arrangements that can reshape local markets. The goal is usually framed
the same way: protect affordability, access, and quality, and keep communities from getting blindsided by a deal that
changes services, prices, or who owns the keys to the clinic. The practical impact is also consistent: more filings,
more timelines, more public scrutiny, and a lot more questions about ownership structuresparticularly when private
equity, real estate investment trusts (REITs), or management services organizations (MSOs) are involved.

Why States Are Turning Up the Volume on Deal Oversight

Healthcare is already heavily regulated, so why add another layer? Because state policymakers and regulators are
worried that consolidation can create higher prices, reduce competition, and narrow patient choicesespecially in
markets where one system already dominates. At the same time, many transactions fall below federal antitrust reporting
thresholds or involve complicated “roll-up” strategies (think: many smaller deals that add up to a big shift over time).

States are also reacting to real-world headlines: hospital financial distress, service line closures, workforce
disruption, and debt-heavy structures that can weaken operations. Some recent scrutiny has focused on financial
engineeringlike sale-leaseback real estate dealsand on governance models where investors may have incentives that
don’t align with patient care. The result is a growing “state deal review” movement that looks less like one single
law and more like a patchwork quilt stitched together by attorneys general, health departments, affordability offices,
and market oversight commissions.

What “Oversight” Actually Means (Hint: It’s Not One Thing)

When people hear “state oversight,” they often picture a regulator who can simply approve or block a deal. In reality,
state regimes vary widely. Think of them on a spectrum:

• Notice-only regimes: Parties must file advance notice with details about the transaction, ownership, and market footprint. The deal may proceed, but regulators can ask questions, share concerns, or refer matters to enforcement agencies.
• Notice + market impact review: A filing can trigger deeper analysissometimes called a cost and market impact reviewoften with public reporting.
• Approval/consent regimes: Some states can impose conditions or deny certain transactions, particularly nonprofit hospital conversions or deals that materially change charitable assets.
• Targeted oversight of structures: Separate from “deal review,” some states are tightening rules around corporate practice of medicine (CPOM) and investor influence over clinical decision-making.

In many states, filings become public (at least in part), which means deal teams now have two audiences: regulators and
everyone else. If that sounds like a PR problem wearing a legal hat, you’re not wrong.

A State-by-State Tour of the New Deal Review Reality

There are too many state approaches to cover exhaustively in one article, but a handful of jurisdictions illustrate
the broader trend and how fast it’s moving.

California: Affordability Oversight Meets Transaction Review

California’s Office of Health Care Affordability (OHCA) has become one of the most closely watched models. Certain
“material change transactions” require advance notice, and OHCA can decide whether to conduct a deeper cost and market
impact review. Practically, this adds a new pre-closing runway: parties need time to prepare filings, respond to
requests for information, and manage potential public attention.

California has also been moving toward broader transparency around investor-backed healthcare activity. Beginning in
2026, new state changes expand oversight of transactions connected to private equity and similar investment players,
with added emphasis on disclosure and structure. Importantly, even where an agency can’t directly “veto” a deal, the
review process can still reshape timing, deal terms, andsometimesthe parties’ willingness to proceed.

Oregon: Health Care Market Oversight With Defined Review Criteria

Oregon’s Health Care Market Oversight (HCMO) program is often cited as a robust approach. It focuses on “material
change transactions” and uses revenue-based thresholds to determine when review is required. Oregon’s framework also
emphasizes policy goals like health equity, cost containment, and accessmeaning parties should be ready to explain not
only what they’re buying, but why the deal helps patients and communities.

Oregon’s system illustrates an important point: state oversight isn’t just about “market share.” It can also include
broader considerations such as financial stability, service availability, and how care delivery will change after the
ink dries.

Massachusetts: A Longtime Model Gets an Upgrade

Massachusetts has been in the deal oversight business for years through its Health Policy Commission (HPC), which
requires notices of material change and can perform cost and market impact reviews. What’s new is the intensified
focus on ownership and controlparticularly for private equity, REIT involvement, and MSO-style structures. Recent
reforms expanded reporting obligations and sharpened the state’s tools for understanding who profits from healthcare
operations and how that affects cost and access.

For dealmakers, Massachusetts is a reminder that “legacy” oversight states aren’t standing still. They’re modernizing
and widening the lensfrom hospital mergers into adjacent areas like outpatient settings and management arrangements.

New York: Material Transaction Reporting and a Faster Clock

New York requires certain “material transactions” to be reported to the Department of Health with advance notice.
Compared with some states, the timeline can be relatively tightmeaning you can’t wait until the last minute to decide
whether a transaction is reportable. New York’s guidance has also clarified that the definition of covered entities
can extend beyond traditional hospitals into a wider set of healthcare players.

The New York approach reflects a growing theme: state oversight is expanding beyond the hospital-centric world and
into the broader ecosystemphysician groups, management entities, dental platforms, labs, and more.

Washington: Attorney General Notice for “Material Change” Transactions

Washington has required notice to the Attorney General for certain transactions that result in a “material change,”
with additional legislative updates that increased required lead time in some cases. The policy discussion in
Washington has also highlighted accessparticularly for essential servicesmaking it a state where parties should be
prepared to discuss continuity of care, charity care policies, and community impact.

Indiana: Notice Requirements and Ownership Reporting

Indiana has been building a more assertive posture through pre-closing notice requirements for certain healthcare
transactions and additional ownership reporting obligations. The direction is clear: more visibility into who owns
healthcare assets, how the market is concentrating, and what the downstream implications might be for patients and
payers.

Connecticut: Notice of Material Change and Active Enforcement

Connecticut combines multiple oversight levers. The state’s Attorney General has authority tied to notice requirements
for certain healthcare transactions, and the state also operates a Certificate of Need (CON) program for major changes
in healthcare facilities, ownership transfers, and service changes. Recent transactions have shown that reviews can
lead to negotiated conditionssuch as commitments affecting pricing behavior or contractual restrictionsunderscoring
that these are not “check-the-box” filings.

Vermont and Colorado: Conversions and Conditions

Some states are especially active when nonprofit hospitals convert, transfer assets, or enter deals that could alter
charitable purposes. Vermont’s Green Mountain Care Board and the state Attorney General, for example, can play roles
in overseeing consolidation and conversion-related activity. Colorado has also had longstanding attention to nonprofit
conversion policy, where public interest considerations often drive conditions or hearing requirements.

What This Means for Healthcare M&A, Private Equity, and “Platform” Strategies

1) Deal timelines are getting longersometimes dramatically

State notice clocks can add 30, 60, 90, or even more days before closingbefore you factor in requests for additional
information or deeper reviews. That affects financing, break fees, outside dates, and integration planning. Even when a
state can’t block a deal outright, the practical effect of extended review can be a deal-killer if parties can’t keep
financing or operational assumptions stable.

2) Smaller deals are no longer “under the radar”

One of the biggest shifts is that state oversight can capture transactions that would never trigger federal reporting.
That includes acquisitions of physician practices, ambulatory centers, or management arrangements that change control
without a traditional “merger.” If your strategy is “buy quietly, integrate later,” states are increasingly saying,
“Not so fastfill out this form first.”

3) Ownership structure is now part of the story, not just a footnote

States are paying closer attention to MSOs, CPOM compliance, related-party arrangements, and where money flows. If a
transaction includes management fees, profit-sharing, real estate leases, or investor protections that look like
backdoor control, expect questions. This doesn’t mean investor-backed healthcare is “banned”it means the model has to
withstand sunlight.

How to Prepare Without Losing Your Mind (or Your Closing Date)

Build a “state notice matrix” early

Before signing, identify where each party operates, which entities are involved (providers, payers, MSOs, pharmacies,
labs), and whether the transaction changes control, governance, or contracting leverage. Then map that to state
thresholds and timelines. The earlier you do this, the less likely you are to discover a 90-day notice requirement
after you’ve promised lenders a 45-day close. (Lenders have long memories and short calendars.)

Draft your “public narrative” like it’s part of the diligence

Many filings become at least partially public. That means the deal rationale needs to be more than “synergies” and
“operational efficiencies.” Regulators and communities want specifics: Will services stay open? Will staffing change?
Will prices increase? Are there commitments around access, charity care, rural coverage, or behavioral health?

Prepare for data requests and documentation friction

State agencies can ask for organizational charts, ownership disclosures, contracting information, financial
projections, and governance documents. Build a clean, consistent story across documents, because inconsistencies are a
magnet for follow-up questions. If you need confidentiality protections for sensitive information, plan that strategy
early toobecause “we’d rather not share” is not a legal standard.

Stress-test clinical independence and CPOM compliance

If your transaction relies on an MSO model or investor-backed operational control, assume you’ll be asked how clinical
decisions remain in the hands of licensed professionals. Contracts and governance should reflect that separation in a
way that’s easy to explain to a regulator who has read too many deal documents and has zero patience for “trust us.”

What Comes Next: More States, More Sectors, More Detail

The direction of travel is unmistakable: more states are adding healthcare transaction oversight, and states that
already have it are expanding scope. Expect a broader set of covered entities (including PBMs, payers, and healthcare
services companies), more ownership transparency, and more scrutiny of serial acquisitions. If you operate nationally,
you’ll increasingly need a 50-state mindset even for deals that used to feel “local.”

The upside is that clearer rules can reduce surprisesif you invest in compliance early. The downside is that “closing”
now often means clearing multiple gates, each with its own paperwork, politics, and timing. Welcome to modern
healthcare dealmaking: bring coffee, bring patience, and bring someone who actually enjoys reading regulations.

Experiences From the Field: of What This Trend Feels Like

If state oversight laws were a weather forecast, deal teams would stop asking, “Will it rain?” and start asking,
“How many umbrellas do we need, and does anyone know where the office keeps them?” The lived experience of expanding
state oversight is less about dramatic courtroom scenes and more about a thousand tiny moments where you realize the
transaction is now a group project with a very serious substitute teacher.

Experience #1: The “Wait, That’s Public?” moment. Someone on the teamoften a perfectly competent person who just had
the misfortune of being optimisticassumes the filing is private. Then they learn that parts of it may be posted
publicly. Suddenly, the draft goes from “legal description” to “public-facing explanation,” and the group discovers
that no one agrees on whether the deal is “an affiliation,” “a strategic partnership,” or “a merger that is
definitely-not-a-merger.” Ten minutes later, you’re debating adjectives like they’re life choices.

Experience #2: The timeline recalibration. The buyer’s model says integration starts right after closing. The state
notice clock says, “That’s adorable.” Everyone scrambles to extend outside dates, renegotiate financing flexibility,
and explain to leadership why “regulatory review” is not a single event but a sequence of events with feelings.
(Mostly the feeling is “please respond within seven days.”)

Experience #3: The org chart Olympics. You know you’re in deep when someone asks for an ownership chart that shows
every entity, every percentage, and every controlling interestplus a version that’s “simplified for humans.” This is
when the team learns two truths: (1) the corporate structure has always been complicated, and (2) it becomes more
complicated the moment you try to explain it out loud.

Experience #4: The “value story” workout. Regulators and stakeholders want to know how the transaction improves care,
access, and affordability. The team starts listing commitments: keeping service lines open, investing in staffing,
maintaining charity care policies, expanding behavioral health, improving scheduling, stabilizing finances. It’s the
part of the process where strategy becomes specificand where vague promises get replaced by measurable statements
that can be tracked later. It’s also where everyone realizes that the best defense is a plan you’d actually want your
neighbor to read.

Experience #5: The MSO/CPOM “show your work” phase. If investors are involved, questions shift from “what’s the deal?”
to “who controls what?” Teams re-check governance language, management fee formulas, and decision rights. They rewrite
clauses to make clinical independence unmistakable. The best teams don’t just aim to “pass review”; they aim to build
a structure that stays durable under scrutiny, because the trend line suggests the scrutiny isn’t going away.

And in the end, most teams walk away with the same hard-earned lesson: oversight isn’t only a hurdle. It’s a forcing
function. It pushes parties to clarify the real-world impact of a healthcare transactionon patients, workers, and
communities. If you can tell that story clearly (with receipts), you’re not just more likely to closeyou’re more
likely to deserve to.